Comprehensive analysis of variation of tumor infiltrating lymphocytes during neoadjuvant chemotherapy in triple-negative breast cancer.
Carlos Castañeda Altamirano(Instituto Nacional de Enfermedades Neoplásicas), Tatiana Vidaurre(The University of Texas MD Anderson Cancer Center), Ketty Dolores Cerna(Instituto Nacional de Enfermedades Neoplásicas), José M. Cotrina(Instituto Nacional de Enfermedades Neoplásicas), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Julio E. Abugattas Saba(Instituto Nacional de Enfermedades Neoplásicas), Miluska Castillo(Instituto Nacional de Enfermedades Neoplásicas), Henry Gómez(National Cancer Center), Carolina B. López(Institute for Women's Policy Research), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Ana M. González-Angulo(The University of Texas MD Anderson Cancer Center), Patricia Arboleda Ezcurra(Instituto Nacional de Enfermedades Neoplásicas), Valeria Villegas Bernaola(Instituto Nacional de Enfermedades Neoplásicas), Yun Wu(The University of Texas MD Anderson Cancer Center), Katerin Ingrid Rojas(Hospital Universitario 12 De Octubre), Maria Teresa Núñez Butrón(Instituto Nacional de Enfermedades Neoplásicas)
Cited by 0
Related Papers
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|988
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684